Serum levels of large tenascin-C variants, matrix metalloproteinase-9, and tissue inhibitors of matrix metalloproteinases in concentric versus eccentric left ventricular hypertrophy

European Journal of Heart Failure

Volumn 11, Issue 11, 2009, Pages 1057-1062

  Franz, Marcus ^a   Berndt, Alexander ^a   Altendorf Hofmann, Annelore ^a   Fiedler, Nico ^a   Richter, Petra ^a   Schumm, Julia ^a   Fritzenwanger, Michael ^a   Figulla, Hans Reiner ^a   Brehm, Bernhard R ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

Hypertension; Left ventricular hypertrophy; MMP 9; Tenascin C; TIMP

Indexed keywords

GELATINASE B; TENASCIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 4;

ADULT; AGED; ARTICLE; CONCENTRIC MUSCLE CONTRACTION; CONTROLLED STUDY; ECCENTRIC MUSCLE CONTRACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART SIZE; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HEART VENTRICLE SEPTUM; HEART VENTRICLE WALL; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THICKNESS;

AGED; BIOLOGICAL MARKERS; FEMALE; GENE EXPRESSION; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; TENASCIN; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TISSUE INHIBITOR OF METALLOPROTEINASES; VENTRICULAR REMODELING;

EID: 70350691882     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfp128     Document Type: Article

References (37)

1. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KKL. The progression from hypertension to chronic heart failure. JAMA 1996;275:1557-1562. (Pubitemid 26154241)
2. Lloyd-Jones DM, Larrson MG, Leip EP, Beiser A, D'Agostino RB, Kannel WB, Murabito JM, Vasan RS, Benjamin EJ, Levy D. Lifetime risk for developing congestive heart failure: the Framingham Study. Circulation 2002;106:3068-3072. (Pubitemid 35440290)
3. Spinale FG. Myocardial matrix remodelling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev 2007;87:1285-1342.
4. Bella JN, Wachtell K, Palmieri V, Liebson PR, Gerdts E, Ylitalo A, Koren MJ, Pedersen OL, Rokkedal J, Dahlöf B, Roman MJ, Devereux RB. Relation of left ventricular geometry and function to systemic hemodynamics in hypertension: the LIFE Study. J Hypertens 2001;19:127-134. (Pubitemid 32099285)
5. Grossmann W, Jones D, McLaurin LP. Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest 1975;56:56-64.
6. Ganau A, Devereux RB, Roman MU, de Simone G, Pickering TG, Saba PS, Vargiu P, Simongini I, Laragh JH. Patterns of left ventricular hypertrophy and geometric remodelling in essential hypertension. J Am Coll Cardiol 1992;19: 1550-1558.
7. Devereux RB, James GD, Pickering TG. What is normal blood pressure? Comparison of ambulatory pressure level and variability in patients with normal and abnormal left ventricular geometry. Am J Hypertens 1993;6:211S-215S.
8. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990;322:1561-1566.
9. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991;114:345-352.
10. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Battistelli M, Bartoccini C, Santucci A, Santucci C, Reboldi G, Porcellati C. Adverse prognostic significance of concentric remodeling of the left ventricle in hypertensive patients with normal left ventricular mass. J Am Coll Cardiol 1995;25:871-878.
11. Weber KT, Sun Y, Guarda E. Structural remodeling in hypertensive heart disease and the role of hormones. Hypertension 1994;23:869-877.
12. López B, González A, Varo N, Laviades C, Querejeta R, D́iez J. Biochemical assessment of myocardial fibrosis in hypertensive heart disease. Hypertension 2001;38:1222-1226.
13. Ahmed SH, Clark LL, Pennington WR, Webb CS, Bonnema DD, Leonardi AH, McClure CD, Spinale FG, Zile MR. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 2006;113:2089-2096.
14. Willems IE, Arends JW, Daemen MJ. Tenascin and fibronectin expression in healing human myocardial scars. J Pathol 1996;179:321-325.
15. Herpel E, Singer S, Flechtenmacher C, Pritsch M, Sack FU, Hagl S, Katus HA, Haass M, Otto HF, Schnabel PA. Extracellular matrix proteins and matrix metal-loproteinases differ between various right and left ventricular sites in end-stage cardiomyopathies. Virchows Arch 2005;446:369-378.
16. Hiroe M, Imanaka-Yoshida K, Yoshida T. The role of tenascin C in the development of myocardial remodelling. Nippon Rinsho 2007;65(Suppl. 4):206-213.
17. Imanaka-Yoshida K, Matsumoto K, Hara M, Sakakura T, Yoshida T. The dynamic expression of tenascin-C and tenascin-X during early heart development in the mouse. Differentiation 2003;71:291-298.
18. Imanaka-Yoshida K, Hiroe M, Yasutomi Y, Toyozaki T, Tsuchiya T, Noda N, Maki T, Nishikawa T, Sakakura T, Yoshida T. Tenascin-C is a useful marker for disease activity in myocarditis. J Pathol 2002;197:388-394.
19. Morimoto S, Imanaka-Yoshida K, Hiramitsu S, Kato S, Ohtsuki M, Uemura A, Kato Y, Nishikawa T, Toyozaki T, Hishida H, Yoshida T, Hiroe M. Diagnostic utility of tenascin-C for evaluation of the activity of human acute myocarditis. J Pathol 2005;205:460-467.
20. Tamaoki M, Imanaka-Yoshida K, Yokoyama K, Nishioka T, Inada H, Hiroe M, Sakakura T, Yoshida T. Tenascin-C regulates recruitment of myofibroblasts during tissue repair after myocardial injury. Am J Pathol 2005;167:71-80.
21. Imanaka-Yoshida K, Hiroe M, Nishikawa T, Ishiyama S, Shimojo T, Ohta Y, Sakakura T, Yoshida T. Tenascin-C modulates adhesion of cardiomyocytes to extracellular matrix during tissue remodelling after myocardial infarction. Lab Invest 2001;81:1015-1024.
22. Aso N, Tamura A, Nasu M. Circulating tenascin-C levels in patients with idio-pathic dilated cardiomyopathy. Am J Cardiol 2004;94:1468-1470.
23. Terasaki F, Okamoto H, Onishi K, Sato A, Shimomura H, Tsukada B, Imanaka-Yoshida K, Hiroe M, Yoshida T, Kitaura Y, Kitabatake A, and Study Group for Intractable diseases by a Grant from the Ministry of Health, Labor Welfare of Japan. Higher serum tenascin-C levels reflect the severity of heart failure, left ventricular dysfunction and remodeling in patients with dilated cardio-myopathy. Circ J 2007;71:327-330.
24. Siri A, Knäuper V, Veirana N, Caocci F, Murphy G, Zardi L. Different susceptibility of small and large human tenascin-C isoforms to degradation by matrix metallo-proteinases. J Biol Chem 1995;270:8650-8654.
25. Spinale FG, Gunasinghe H, Sprunger PD, Baskin JM, Bradham WC. Extracellular degradative pathways in myocardial remodeling and progression to heart failure. J Card Fail 2002;8(Suppl. 6):S332-S338. (Pubitemid 36083080)
26. Chapman RE, Spinale FG. Extracellular protease activation and unravelling of the myocardial interstitium: critical steps toward clinical applications. Am J Physiol Heart Circ Physiol 2004;286:H1-H10.
27. Fielitz J, Leuschner M, Zurbrugg HR, Hannack B, Pregla R, Hetzer R, Regitz-Zagrosek V. Regulation of matrix metalloproteinases and their inhibitors in the left ventricular myocardium of patients with aortic stenosis. J Mol Med 2004;82:809-820.
28. Heymans S, Schroen B, Vermeersch P, Milting H, Gao F, Kassner A, Gillijns H, Herijgers P, Flameng W, Carmeliet P, Van de Werf F, Pinto YM, Janssens S. Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart. Circulation 2005;112: 1136-1144.
29. Polyakova V, Hein S, Kostin S, Ziegelhoeffer T, Schaper J. Matrix metalloprotei-nases and their tissue inhibitors in pressure-overloaded human myocardium during heart failure progression. J Am Coll Cardiol 2004;44:1609-1618.
30. Chancey AL, Brower GL, Peterson JT, Janicki JS. Effects of matrix metalloprotei-nase inhibition on ventricular remodeling due to volume overload. Circulation 2002;105:1983-1988.
31. Yan AT, Yan RT, Spinale FG, Afzal R, Gunasinghe HR, Arnold M, Demers C, McKelvie RS, Liu PP. Plasma matrix metalloproteinase-9 level is correlated with left ventricular volumes and ejection fraction in patients with heart failure. J Card Fail 2006;12:514-519.
32. Krumholz HM, Larson M, Levy D. Prognosis of left ventricular geometric pattern in the Framingham Heart Study. J Am Coll Cardiol 1995;25:879-884.
33. Sato A, Aonuma K, Imanaka-Yoshida K, Yoshida T, Isobe M, Kawase D, Kinoshita N, Yazaki Y, Hiroe M. Serum tenascin-C might be a novel predictor of left ventricular remodelling and prognosis after acute myocardial infarction. J Am Coll Cardiol 2006;47:2319-2325.
34. Hessel MH, Bleeker GB, Bax JJ, Henneman MM, den Adel B, Klok M, Schalij MJ, Atsma DE, van der Laarse A. Reverse ventricular remodelling after cardiac resyn-chronization therapy is associated with a reduction in serum tenascin-C and plasma matrix metalloproteinase-9 levels. Eur J Heart Fail 2007;9:1058-1063.
35. Bonnema DD, Webb CS, Pennington WR, Stroud RE, Leonardi AE, Clark LL, McClure CD, Finklea L, Spinale FG, Zile MR. Effects of age on plasma matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs). J Card Fail 2007;13:530-540.
36. Yang YJ, Zhang X, Zhu WL, Huang Y. Involvement of matrix metalloproteinases in the regulation of myocardial extracellular matrix in patients with congestive heart failure. Zhonghua Yi Xue Za Zhi 2006;86:1693-1696.
37. George J, Patal S, Wexler D, Roth A, Sheps D, Keren G. Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure. Am Heart J 2005;150:484-487.